Efeitos maleato de timolol 0.5% do cloridrato de dorzolamida 2%, e da associação de ambas na pressão intra-ocular

Borges, A. G.; Brandão, Cláudia Valéria Seullner; Ranzani, José Joaquim Titton; Adalberto, J. C.

doi:10.1590/s0102-09352007000300017

Cited by 5 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results were similar to those described in a previous research conducted in healthy dogs, that also reported the efficaciousness of the combination of dorzolamide/timolol in reducing the IOP (BORGES et al, 2007). Notwithstanding, BORGES et al (2007) assessed the IOP-lowering effect of the fixed combination of dorzolamide/timolol after a single instillation, for only eight hours, and only considered to compare the effect of the treated eye with the control eye.…”

Section: Resultssupporting

confidence: 90%

“…When dorzolamide is used as a monotherapy, the drug significantly decreases IOP in healthy and glaucomatous dogs (CAWRSE et al, 2001;GELATT & MACKAY, 2001). However, the fixed combination of dorzolamide with timolol maleate, a nonselective beta blocker, proved to be more effective than dorzolamide alone, in reducing the IOP and pupil diameter (PD) in glaucomatous and healthy dogs (PLUMMER et al, 2006;BORGES et al, 2007).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of dorzolamide/timolol and tafluprost on intraocular pressure and pupil diameter in healthy dogs

et al. 2017

View full text Add to dashboard Cite

This study aimed to evaluate and compare the effects of the fixed combination of dorzolamide/timolol with those of tafluprost on intraocular pressure (IOP) and pupil diameter (PD) in healthy dogs (n=10). Two experiments were conducted with an interval of 30 days. In both, IOP and PD were assessed at 8, 11, 14, 17, and 20h. Parameters were evaluated during baseline, treatment period of four days, and one day of post-treatment. During treatment phase, IOP decreased by 0.74 (P<0.05), 1.88 (P<0.01), 2.94 (P<0.001), and 3.10mmHg (P<0.01), in dorzolamide/timolol-treated eyes; and by 1.50, 2.18, 2.14, and 2.18mmHg (P<0.001), in tafluprost-treated eyes. PD decreased by 0.24 (P<0.01), 0.32 (P<0.01), 0.49 (P<0.001), and 0.40mm (P<0.001), in dorzolamide/timolol treated eyes; and by 2.31, 2.55, 2.43, and 2.70mm (P<0.001), in tafluprost-treated eyes. Dorzolamide/timolol and tafluprost were able to decrease IOP and PD in healthy dogs. However, a cumulative effect of the fixed combination of dorzolamide/timolol was more effective in reducing IOP, than tafluprost. Comparisons between treatments showed that tafluprost was more effective in reducing PD throughout the treatment phase.

show abstract

Section: Resultssupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

Effects of dorzolamide/timolol and tafluprost on intraocular pressure and pupil diameter in healthy dogs

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Para estimativa dos efeitos adversos sob a superfície ocular realizou-se exame sistemático das pálpebras e suas margens, das conjuntivas, córnea e caracterização da secreção ocular com auxílio de oftalmoscópio direto 3 (Beta 200) com feixe de luz em fenda e filtro azul, diariamente. Além da avaliação oftalmológica diária, foi mensurada a espessura corneana central (ECC) com paquímetro ultra-sônico 4 no início e ao final do experimento.…”

Section: Protocolo De Avaliação Oftalmológicaunclassified

“…O glaucoma é uma neuropatia óptica progressiva multifatorial [4,26] que possui como principal fator de risco para o seu desenvolvimento o aumento da pressão intraocular (PIO) [6]. Reveste-se de singular importância por ser considerada a principal causa de cegueira irreversível em seres humanos e cães.…”

Section: Introductionunclassified

See 1 more Smart Citation

Effects of 2% Dorzolamide Hydrochloride and 0.005% Latanoprost Solutions on the Eye Surface of Rabbits

Barbosa

Silva

Melo

2020

Acta Scientiae. Vet.

View full text Add to dashboard Cite

Background: The glaucoma is a progressive optical neuropathy generally associated to the increase of the intraocular pressure (IOP). It is a disease of difficult therapeutic conduct and potential cause of blindness. The dorzolamide at 2% and the latanoprost at 0.005% are topical antiglaucoma drugs that cause significant reduction of the IOP. We decided to evaluate the local adverse effects of the dorzolamide at 2% and of the latanoprost at 0.005% in rabbits treated during 120 days.Materials, Methods & Results: Eighteen adult male rabbits were used in this study. They were randomly distributed into 3 groups (G) [n = 6]. Each animal received topical treatment in both eyes: GI (latanoprost at 0.005%, SID); GII (dorzolamide at 2%, TID) and GIII (ultra-pure water, TID) during 120 days. Ophthalmological evaluation was carried out through daily clinical examination, and at the end of the 120 days of treatment, it was verified clinical-ophthalmological alterations in the eyelids. The measurement of ECC was performed in triplicate, obtaining the lowest value among them as a result. They were carried out at the same time, in the morning between 9 and 10 am in order to avoid the effects of daytime ECC variation related to corneal hydration. In animals from group I, changes were observed in two eyes. Conjunctival hyperemia and ocular secretion, both in mild degree, were evidenced, respectively, in 13.75% and 9.1% of the observations. Conjunctival hyperemia was characterized from the 16th day and lasted until the final time (120 days). The animals from GII, treated with dorzolamide at 2%, presented the highest number of ophthalmological alterations. At the end of the experiment, conjunctival and eyelid changes and presence of ocular secretion, both ranging from mild to moderate, were observed in 60% and 16.32% of eyes, respectively. The animals from control group, GIII, did not present ophthalmological alterations.Discussion: Clinical signs observed in eyes treated with 0.005% latanoprost and 2% dorzolamide hydrochloride demonstrated manifestations of toxicity and / or ocular allergy. The adverse effects described may be related to the preservative of eye drops, benzalkonium chloride, a quaternary ammonia, which demonstrated ocular tissue toxicity, in vivo and in vitro. Benzalkonium chloride present in antiglacomatous drugs can cause conjunctival inflammation affecting the normal immunological functions of the eye. The presence of the preservative mainly justifies the changes found in the group of animals treated with 0.005% latanoprost, considering that the concentration of benzalkonium chloride in this drug is 0.02%, that is, two and a half times greater than of 2% dorzolamide, which is 0.008%. It should be noted that deleterious effects were associated. The other hypothesis associated with the adverse effects observed in the 2% dorzolamide treated group is related to the pH of the drug. This eye drop has a pH of 5.6, while that of 0.005% latanoprost is 6.7. This indicates that 2% dorzolamide may have secondarily induced ocular changes by virtue of its acidic pH. The association of low pH and the presence of benzalkonium chloride in concentration above 0.005% as a preservative of eye drops explains the high percentage of changes observed in this group. When facing the results, one can conclude that the treatment with the latanoprost at 0.005% and dorzolamide at 2% promoted clinical alterations to the eyelids and the conjunctive of rabbits.

show abstract

Ocular echobiometry and relationship with cranial and body morphometric parameters in Shih Tzu dogs

Santos

Zacarias

Porto

et al. 2022

Arq. Bras. Med. Vet. Zootec.

View full text Add to dashboard Cite

The purpose of this paper is to determine the ocular echobiometry and investigate its correlation with cranial and body morphometric parameters in 50 adult Shih Tzu dogs. The echobiometric measurements of the anterior chamber (AC), vitreous chamber (VC), lens axial thickness (LTA), transverse lens thickness (LTT), and axial length of the eyeball (ALE) were obtained by two-dimensional ultrasonography. Morphometric measurements of bizygomatic distance (BDIST), frontal-occipital distance (FOD), withers height (WH), thoracic circumference (TC), and body length (BL) were also obtained. The mean of the AC depth was 2.83±0.50mm, the VC was 9.18±0.54mm, the LTA was 6.42±0.32mm and the LTT was 9.17±1.18mm, while the mean of the ALE was 18.82±0.66mm. There was no correlation between ocular echobiometric variables and cranial and body morphometric variables in adult dogs of the Shih Tzu breed, as well as no significant difference of these variables when considering gender and age of the dogs (p ≥ 0.05).

show abstract

Efeitos maleato de timolol 0.5% do cloridrato de dorzolamida 2%, e da associação de ambas na pressão intra-ocular

Cited by 5 publications

References 17 publications

Effects of dorzolamide/timolol and tafluprost on intraocular pressure and pupil diameter in healthy dogs

Effects of dorzolamide/timolol and tafluprost on intraocular pressure and pupil diameter in healthy dogs

Effects of 2% Dorzolamide Hydrochloride and 0.005% Latanoprost Solutions on the Eye Surface of Rabbits

Ocular echobiometry and relationship with cranial and body morphometric parameters in Shih Tzu dogs

Contact Info

Product

Resources

About